Clinical Trial Update: Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating orelabrutinib plus rituximab with optional autologous hematopoietic stem cell transplantation for mantle cell lymphoma is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Mantle Cell Lymphoma (MCL) | Phase 2 | Status: RECRUITING